← All indications
Lipid Metabolism Disorders
Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.
Subtype terms (5)
More specific conditions that are subtypes of Lipid Metabolism Disorders in the MeSH hierarchy.
- Dyslipidemias
291 drugs (93 approved, 198 experimental)
- Lipid Metabolism, Inborn Errors
6 drugs (2 approved, 4 experimental)
- Lipodystrophy
34 drugs (27 approved, 7 experimental)
- Lipomatosis
1 drug approved
- Xanthomatosis
1 drug approved
Drugs by status
Phase 4 trials (10)
Phase 3 trials (4)
Phase 2 trials (4)
Phase 1 trials (11)
Other trials (27)
Organizations
Organization Involved with Phase 4 Indications (12)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (4)
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (19)
- Unilever
- Indena S.p.A
- Barmherzige Brüder Vienna
- Maastricht University
- Centre National d'Etudes Spatiales
- Federal University of Rio Grande do Sul
- Universidade Estadual de Londrina
- Capital Medical University
- Purdue University
- University of Chester
- University of Sao Paulo
- University of Mississippi
- University of Paris
- Institut Elevage
- Institut technique d'études et de recherches des corps gras
- TERRES INOVIA
- Almond Board of California
- Bioriginal
- National Institute of Nutrition, Vietnam